The Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer Prior to any Systematic Therapy: A Systematic Review

Author(s): Sepideh Mansouri, Parisa Mokhtari-Hesari, Fatemeh Naghavi-al-Hosseini, Keivan Majidzadeh-A, Leila Farahmand*.

Journal Name: Current Stem Cell Research & Therapy

Volume 14 , Issue 6 , 2019

Become EABM
Become Reviewer

Abstract:

Background: Numerous studies have defined the outstanding role of circulating tumor cells (CTC) in the management of cancer, particularly the ones in association with primary tumor metastases.

Objective: The overall aim of the present study was to investigate whether CTCs may serve as a clinical prognostic marker for survival in primary breast cancer.

Methods: Articles Published from June 2011 to July 2017 in PubMed, EMBase, and Cochrane library databases were thoroughly screened for selecting the ones meeting the inclusion criteria.

Result: Studies applying CellSearch® method demonstrated the risk ratios (RR) of 2.51 (95% CI: 1.78- 3.54), 3.98 (95% CI: 2.28- 6.95), 5.59 (95% CI: 3.29- 9.51), and 3.38 (95% CI: 1.88- 6.06) for death rate and relapse rates of 2.48 (95% CI: 1.89 - 3.26), 3.62 (95% CI: 2.37 - 5.51), 4.45 (95% CI: 2.94 - 6.73), and 2.88 (95 % CI: 1.99 - 4.17) at four CTC positive cut points (≥ 1, ≥ 2, ≥ 3, and ≥ 5 CTCs/7.5 ml). Two studies applying the AdnaTest® also documented increased death (RR: 1.38, 95 % CI: 0.42- 4.49) and relapse rates (RR: 2.97, 95 % CI: 1.23 - 7.18)).

Conclusion: Results of this meta-analysis allude CTCs as potent prognostic markers in primary breast cancers prior to any systemic therapy especially when it is studied via CellSearch® administration, considering that the more the CTCs, the greater the death and relapse rates.

Keywords: Breast cancer, CTC, death rate, primary, prognosis, relapse rate.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 6
Year: 2019
Page: [519 - 529]
Pages: 11
DOI: 10.2174/1574888X14666190306103759
Price: $58

Article Metrics

PDF: 24